DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency
– Transaction adds another innovative rare disease therapy to DRI’s expanding portfolio – – Deal structure offers risk sharing with milestone payments for positive performance – –…
DRI Healthcare Trust Reports Third Quarter 2022 Results
– Transactions for Empaveli, Zejula and Omidria royalties mark significant progress – – Cash receipts expected to be flat to slightly increasing through 2025 even with no further deployment – -…
DRI Healthcare Trust Announces Appointment of Poonam Puri to Board of Trustees
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced Poonam Puri has been appointed as an independent member of the Trust’s board of trustees effective…
DRI Healthcare Trust to Host Third Quarter Earnings Call and Webcast on November 8, 2022
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today it will hold a conference call to discuss its third quarter 2022 financial results on Tuesday, November 8,…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Omidria® for Intracameral Use During Cataract Surgery or Intraocular Lens Replacement
– Transaction adds a well-established ophthalmology product that generates substantial near-term cash flows, with long-term structural growth anticipated – – Third transaction of 2022 with US$184.5 million deployed YTD – – DRI to hold conference call to provide business update at 10:00 am ET this morning – TORONTO, Oct. 3, 2022 /CNW/ – DRI Healthcare […]
DRI Healthcare Trust Provides Update on Natpara Royalty
TORONTO, Oct. 3, 2022 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that, based on its ongoing review of its royalty entitlement on Natpara (the “Natpara Royalty”), DRI has concluded that the issues that led to the 2019 recall of Natpara in the United States are likely to […]
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in Zejula®, Currently Approved for the Treatment of Ovarian Cancer with Additional Indications Under Development
– Zejula’s multiple pipeline indications offer significant upside potential – – Transaction builds on DRI’s history of investing in innovative oncology therapies – – Long-term asset with strong intellectual property protection – TORONTO, Sept. 12, 2022 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that a wholly-owned subsidiary […]
DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences
TORONTO, Aug. 4, 2022 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that the Trust will participate in the following investor conferences in August and September: Canaccord Genuity Annual Growth Conference Date: August 10, 2022 Presentation time: 9:00 am ET City: Boston, Massachusetts Event URL: https://www.canaccordgenuity.com/capital-markets/about-us/events/42nd-annual-growth-conference/ CIBC Eastern […]
DRI Healthcare Trust Reports Second Quarter 2022 Results
– Continued strong financial results and cash generation from existing assets – – Addition of pegcetacoplan to royalty portfolio subsequent to quarter end – TORONTO, Aug. 3, 2022 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced its financial results for the quarter ended June 30, 2022. The Trust’s second […]
DRI Healthcare Trust to Host Second Quarter Earnings Call and Webcast on August 4, 2022
TORONTO, July 21, 2022 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today it will hold a conference call to discuss its second quarter 2022 financial results on Thursday, August 4, 2022, at 8:30 a.m. ET. The Trust will report its financial results on Wednesday, August 3, 2022, after market […]